Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery. (2022)
Attributed to:
Blood borne viruses
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1164/rccm.202112-2836oc
PubMed Identifier: 35580040
Publication URI: http://europepmc.org/abstract/MED/35580040
Type: Journal Article/Review
Volume: 206
Parent Publication: American journal of respiratory and critical care medicine
Issue: 6
ISSN: 1073-449X